Product Finder

Select by:

View all products
View all news

Other Products from this Line

Enolex

Packages containing 28 coated tablets.

 


View more

Tinactol

Packaging containing 30 coated tablets.


View more

Geniceral

Packets of 30 and 60 tablets.


View more

Tiarix CR

Controlled release coated tablets, 12.5 and 25 mg: Packs containing 30 controlled release coated tablets.


View more
You are in:
HomeProductsValcas

Product Line:

Neurology and Psychiatry Line

Patient Product Information

Formulation:
Sodium divalproate 269,10 mg; Excipients  q.s; Sodium divalproate 538,20 mg; Excipients  q.s

 

Composition: VALCAS 250 - Each coated tablet contains: sodium divalproate (equivalent to 250 mg of valproic acid) 269.10 mg. Excipients q.s. VALCAS 500 - Each coated tablet contains: sodium divalproate (equivalent to 500 mg of valproic acid) 538.20 mg. Excipients: q.s.

Therapeutic action: anticonvulsant. Treatment of bipolar disorder. Migraine prophylaxis.

Indications: Epilepsy: VALCAS is indicated as a monotherapy and in combination for patients with partial and complex crisis that occur in isolation or associated with other type of crisis.

VALCAS is also indicated as a monotherapy or in combination in the treatment of patients with simple and complex absence crisis, and as an adjuvant in patients with multiple crisis that include absence.

Mania: VALCAS is indicated for the treatment of maniac episodes associated with bipolar disorder.

Migraine: VALCAS is indicated for the prophylaxis of migraines. 

Valproic acid may be harmful for the fetus; therefore, the use of VALCAS should be considered in women of childbearing potential only after a thorough discussion about this risk with the patient and after assessing its use against the potential drug benefits.

Dosage: Epilepsy: initially, 10-15 mg/kg/day. Up to 60 mg/kg/day. Mania: initially, 750 mg/day (split dose). Maximum recommended dose: 60 mg/kg/day. Migraine: initially, 500 mg/day (divided in two doses). Up to 1 g/day.

Contraindications: liver disease or significant hepatic impairments, patients with known urea cycle disorders, hypersensitivity to the drug or to any of the Medicinal Specialty components.

Hoy supplied: packages containing 50 coated tablets.